The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome


Por: Pérez de Llano L, Dacal Rivas D, Marina Malanda N, Plaza Moral V, Gullón Blanco JA, Muñoz-Esquerre M, García-Moguel I, Díaz Campos RM, Martínez-Moragón E, Harbenau Mena A, Cosío BG, Padilla Galo A and Cisneros Serrano C

Publicada: 1 ene 2022 Ahead of Print: 18 mar 2022
Resumen:
Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with >= 1 exacerbation and >= 1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT >= 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.

Filiaciones:
Pérez de Llano L:
 Pneumology Service, Hospital Lucus Augusti, EOXI Lugo, Cervo e Monforte, Lugo, Spain

Dacal Rivas D:
 Pneumology Service, Hospital Lucus Augusti, EOXI Lugo, Cervo e Monforte, Lugo, Spain

Marina Malanda N:
 Pneumology Service, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain

Plaza Moral V:
 Pneumology Service, Hospital Sta Creu i Sant Pau, Barcelona, Spain

Gullón Blanco JA:
 Pneumology Service, University Hospital San Agustín, Avilés, Spain

Muñoz-Esquerre M:
 Pneumology Service, Hospital Bellvitge-IDIBELL, Barcelona, Spain

García-Moguel I:
 Allergy Service, Hospital 12 de Octubre, Madrid, Spain

Díaz Campos RM:
 Pneumology Service, Institute for Health Research (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain

:
 Pneumology Service, Hospital Doctor Peset, Valencia, Spain

Harbenau Mena A:
 Allergy Service, Hospital de Mérida, Badajoz, Spain

Cosío BG:
 Pneumology Service, Hospital Universitario Son Espases-IdISBa-CIBERES, Palma de Mallorca, Spain

Padilla Galo A:
 Pneumology Service, Hospital Costa del Sol, Marbella, Málaga, Spain

Cisneros Serrano C:
 Pneumology Service, Hospital Universitario de La Princesa, Madrid, Spain
ISSN: 11786965





Journal of Asthma and Allergy
Editorial
Dove Medical Press Ltd, PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND, Nueva Zelanda
Tipo de documento: Article
Volumen: 15 Número:
Páginas: 363-369
WOS Id: 000773456700001
ID de PubMed: 35330786
imagen Green Published, gold

MÉTRICAS